Alder BioPharmaceuticals Culture Company

Mr. Larry Benedict has been Principal Accounting Officer and Executive Vice President of Finance at Alder Biopharmaceuticals Inc. since October 11, 2016. Mr. Benedict served as Senior Vice President of Finance at Alder Biopharmaceuticals Inc. from January 2013 to October 11, 2016. Mr. Benedict served as Vice President of Finance at Alder Biopharmaceuticals Inc. since joined it in June 2008. Mr. Benedict has over 25 years of financial experience. Prior to joining Alder, he served in various positions at Seattle Genetics, Inc., most recently as Director of Finance and Controller in charge of all accounting and finance activities to take Seattle Genetics from a pre-IPO to a post-IPO NASDAQ publicly traded company. Other previous positions include Chief Financial Officer at Sensible Solutions, Inc., a financial software consulting company; Finance Manager at SmithKline Beecham Clinical Laboratories; and various finance roles at Bristol-Myers Squibb. Mr. Benedict is a CPA-Inactive certificate holder in Washington State. He received a B.S. in Accounting from Central Washington University.

Dr. John A. Latham, Ph.D. co-founded Alder Biopharmaceuticals Inc. in May 2002 and has been its Chief Scientific Officer since May 2002 and also serves as its Head of Research & Development. Prior to, Dr. Latham served as Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994 he joined Darwin Molecular, a first-generation gene-to-drug Biotechnology Company, as a founding director. His responsibilities included translating novel genes into therapeutic targets and ultimately providing a first-generation therapeutic agent. His efforts were centered in inflammation, autoimmune diseases and osteoporosis and provided important components to Celltech's therapeutic pipeline. The osteoporosis research led by him provided the underpinning for the Amgen/Celltech collaboration for the development of novel therapeutics to treat bone disorders. Prior to working at Darwin Molecular, he was one of the first scientists hired by Gilead Sciences and a member of a core group established to exploit novel oligonucleotide-based technologies. As a member of this team, he played a critical role in developing and implementing technology that enabled Gilead Sciences to establish itself as a leader in the field of random oligonucleotide selection biochemistry. He received his Ph.D. in Biochemistry from the Massachusetts Institute of Technology in the laboratory of Professor Christopher Walsh and conducted post-graduate research with Professor Thomas Cech at the University of Colorado, Boulder.

Ms. Elisabeth A. Sandoval, also known as Lisa, M.B.A. has been Chief Commercial Officer and Executive Vice President of Corporate Strategy of Alder Biopharmaceuticals Inc. since August 2016 and January 1, 2018 respectively. Ms. Sandoval serves as Marketing Director of Scottsdale Healthcare Corp. Ms. Sandoval served as the Chief Commercial Officer of Kythera Biopharmaceuticals, Inc. since March 2012. Prior to joining Kythera in 2012, she served as Vice President of Global Marketing at IOLAB Corp. (Formerly known as, Bausch & Lomb Surgical, Inc.). Ms. Sandoval served as Vice President of Global Marketing at Bausch & Lomb Incorporated since November 4, 2010. She served as Vice President of Global Strategic Marketing for Allergan Medical, where she drove the launch of the market-leading Juvederm dermal filler and established its worldwide marketing team. Ms. Sandoval has 30 years of experience in the pharmaceutical and medical device industry spanning research and development, sales management, marketing strategy and commercial launch planning and execution. She began her career with Ethicon, a subsidiary of Johnson & Johnson in research and development. She then joined Allergan, moving from R&D into sales and marketing roles that spanned over 20 years. She earned a BS in Biology from the University of California, Irvine and an MBA from Pepperdine University.

Dr. Timothy M. Whitaker, M.D. is a Consultant of Alder Biopharmaceuticals, Inc. since January 1, 2018. He was Medical Officer at Shire Development Inc. Dr. Whitaker was the Chief Medical Officer at Alder Biopharmaceuticals Inc. since June 29, 2016 until December 31, 2017. He has 20 years of experience in the pharmaceutical industry leading and managing global clinical development programs, including the strategic direction of multiple neuroscience clinical programs while achieving numerous global regulatory approvals. Dr. Whitaker joined Alder from Shire plc, where he has held clinical development positions of increasing responsibility since 2004, most recently as the vice president and neuroscience therapeutic area head of global clinical development. During his tenure, he played a key role in developing Shire as a world leader in specialty pharmaceuticals. From 1996 to 2004, Dr. Whitaker held the positions of associate director, director and senior director of clinical research and development, neuroscience divisions, at Wyeth. Prior to that, he held a variety of teaching and clinical appointments at the University of Vermont College of Medicine and the Medical Center Hospital of Vermont, including Associate Professor of Psychiatry and Director of the Psychopharmacology Clinic. He holds a bachelor's degree from Duke University in Durham, N.C., and a medical degree from Wake Forest University School of Medicine in Winston-Salem, N.C. He completed a residency in psychiatry and a fellowship in clinical psychopharmacology at the Medical Center Hospital of Vermont in Burlington.

Angela Willis serves as the Vice President, Market Access of Alder Biopharmaceuticals Inc. (Nasdaq: ALDR). Angela started at Alder Biopharmaceuticals Inc. (Nasdaq: ALDR) in February of 2019. Angela currently resides in the Greater Los Angeles Area.

Paul Cleveland serves as the Chair Of The Board Of Directors of Alder Biopharmaceuticals Inc. (Nasdaq: ALDR). Paul started at Alder Biopharmaceuticals Inc. (Nasdaq: ALDR) in October of 2018. Paul currently resides in the Greater San Diego Area.

Scott Riccio serves as the Head of Patient and Professional Engagement of Alder Biopharmaceuticals Inc. (Nasdaq: ALDR). Scott started at Alder Biopharmaceuticals Inc. (Nasdaq: ALDR) in January of 2019. Scott currently resides in the Greater Seattle Area.

Carlos Campoy serves as the Chief Financial Officer of Alder Biopharmaceuticals Inc. (Nasdaq: ALDR). Carlos started at Alder Biopharmaceuticals Inc. (Nasdaq: ALDR) in December of 2018. Carlos currently resides in the Greater Seattle Area.

Elisabeth Sandoval serves as the Chief Commercial Officer and EVP Corporate Strategy of Alder Biopharmaceuticals Inc. (Nasdaq: ALDR). Elisabeth started at Alder Biopharmaceuticals Inc. (Nasdaq: ALDR) in August of 2016. Elisabeth currently resides in the Orange County, California Area.